| ［1］ |
Villa⁃Ruiz C, Lo K, Desai S, et al. Practice gaps in the evaluation of systemic involvement in patients with cutaneous sarcoidosis presenting to a dermatologist: a retrospective review of 48 patients［J］. J Am Acad Dermatol, 2021,85（3）:794⁃796. DOI: 10.1016/j.jaad.2020.10.021.
|
| ［2］ |
缪秋菊, 宋昊, 王逸飞, 等. 皮下结节型结节病八例临床病理分析［J］. 中华皮肤科杂志, 2019,52（11）:808⁃811. DOI: 10. 35541/cjd.20190323.
|
| ［3］ |
Dhattarwal N, Ramesh V. Tuberculids: a narrative review［J］. Indian Dermatol Online J, 2023,14（3）:320⁃329. DOI: 10.4103/idoj.idoj_284_22.
|
| ［4］ |
Kaul S, Kaur I, Mehta S, et al. Cutaneous tuberculosis. Part Ⅰ: pathogenesis, classification, and clinical features［J］. J Am Acad Dermatol, 2023,89（6）:1091⁃1103. DOI: 10.1016/j.jaad.2021. 12.063.
|
| ［5］ |
Matsuda T, Kambe N, Ueki Y, et al. Clinical characteristics and treatment of 50 cases of Blau syndrome in Japan confirmed by genetic analysis of the NOD2 mutation［J］. Ann Rheum Dis, 2020,79（11）:1492⁃1499. DOI: 10.1136/annrheumdis⁃2020⁃217320.
|
| ［6］ |
Bordignon M, Rottoli P, Agostini C, et al. Adaptive immune responses in primary cutaneous sarcoidosis［J］. Clin Dev Immunol, 2011,2011:235142. DOI: 10.1155/2011/235142.
|
| ［7］ |
Damsky W, Wang A, Kim DJ, et al. Inhibition of type 1 immunity with tofacitinib is associated with marked improvement in longstanding sarcoidosis［J］. Nat Commun, 2022,13（1）:3140. DOI: 10.1038/s41467⁃022⁃30615⁃x.
|
| ［8］ |
Redl A, Doberer K, Unterluggauer L, et al. Efficacy and safety of mTOR inhibition in cutaneous sarcoidosis: a single⁃centre trial［J］. Lancet Rheumatol, 2024,6（2）:e81⁃e91. DOI: 10.1016/S2665⁃9913（23）00302⁃8.
|
